tbuckley/cabot-search huggingface dataset:
GASTROINTESTINAL BLEEDING
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Author’s Name
Authors: Jesper Lagergren, Giola Santoni, Nora Disis, Lee Ellis
Journal: JAMA Oncology (2019)

Abraham S. Kanate, MBBS; Ambuj Kumar, MD, MPH; Peter Dreger, MD; Martin Dreyling, MD; Steven Le Gouill, MD; Paolo Corradini, MD; Chris Bredeson, MD, MSc, FRCPC; Timothy S. Fenske, MD; Sonali M. Smith, MD; Anna Sureda, MD; Alison Moskowitz, MD; Jonathan W. Friedberg, MD; David J. Inwards, MD; Alex F. Herrera, MD; Mohamed A. Kharfan-Dabaja, MD; Nishitha Reddy, MBBS; Silvia Montoto, MD; Stephen P. Robinson, MD; Syed A. Abutalib, MBBS; Christian Gisselbrecht, MD; Julie Vose, MD; Ajay Gopal, MD; Mazyar Shadman, MD; Miguel-Angel Perales, MD; Paul Carpenter, MD; Bipin N. Savani, MD; Mehdi Hamadani, MD
Manuscripts Approved for JNCI, December 10, 1963, to January 10, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Manuscripts Approved for JNCI, December 10, 1963, to January 10, 1964 Get access JNCI: Journal of the National Cancer Institute, Volume 32, Issue 2, February 1964, Page 533, https://doi.org/10.1093/jnci/32.2.533 Published: 01 February 1964
Hans Reiter Died Nov 25,1969
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PULMONARY DISEASES
Authors: Roger S. Mitchell, Giles F. Filley
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Authors' Reply
Authors: Syazrah Salam, Arif Khwaja, Richard Eastell
Journal: Journal of the American Society of Nephrology (2018)

We thank Gosmanova and Gosmanova1 for highlighting the potential of total alkaline phosphatase (tALP) to identify patients with abnormal bone turnover. We agree that tALP is inexpensive and more readily available, but it measures alkaline phosphatase from various sources, including the liver, bone, intestine, and placenta. In our study, ten of 43 patients who had bone biopsy had tALP level above the reference range. Only one of these patients had elevated γ-glutamyl tranferase but with normal transaminases. Hence, our finding is applicable to patients with CKD without liver disease. Even so, we found that tALP had area under the curve (AUC) of 0.67 for identifying high bone turnover, whereas intact parathyroid hormone (iPTH) had AUC of 0.76.2 Both AUCs were <0.80, but iPTH had higher specificity and positive predictive value. Hence, in this situation, we would still use iPTH to identify those with high bone turnover. For identifying low bone turnover, tALP had AUC of 0.753 and was not significantly better than iPTH AUC. However, we agree that the predictive values were comparable with those for bone alkaline phosphatase. Hence, tALP could be used with the caveats that liver disease has been excluded and the clinician accepts that the test is not as robust as bone alkaline phosphatase. For reporting diagnostic accuracy, strictly only bone turnover markers with AUC>0.80 can be labeled as the tests robust enough to be an alternative to bone biopsy. As pointed out in the editorial relating to our article, these bone turnover markers were not perfect tests to replace bone biopsy, and we must continue our search for better noninvasive tests.3 Using tALP in clinical setting will need to be balanced between the availability of the tests and its suboptimal diagnostic accuracy. Disclosures S.S. has received research grant and support from Immunodiagnostics Systems. R.E. has received grants and consulting fees from Immunodiagnostics Systems and Roche Diagnostics. A.K. has no financial support to declare.
A CASE OF OSTEITIS FIBROSA CYSTICA (OSTEOMALACIA?) WITH EVIDENCE OF HYPERACTIVITY OF THE PARATHYROID BODIES. METABOLIC STUDY III
Authors: W. S. McClellan, R. R. Hannon
Journal: Journal of Clinical Investigation (1930)

The case history of the patient C. M. and observations of his calcium and phosphorus metabolisms both before and after the removal of two parathyroid bodies have been presented in Papers I and II of this series (1, 2).After the patient left the Massachusetts General Hospital he spent one month at home and then was readmitted to the metabolism ward of the Russell Sage Institute of Pathology, Novem- ber 1, 1926.He returned for a period of stretching to see if his de- formities could be completely or partially corrected.During this stay in the hospital further observations were made to see the effect of various diets and medicines on his mineral metabolism. CLINICAL COURSEAfter roentgenograms were taken to compare with the earlier find- ings, the head of the patient's bed was elevated to an angle of 30 degrees and traction was applied by weights attached to a leather collar.The traction was continued for four and one-half months and during this time he was not allowed to sit up.He maintained his physical condition by various gymnastic exercises daily during the time when his bed was lowered.His height on admission was 168 cm.The maximum height during the period of stretching was 170 cm.He first sat up by himself April 1, 1927 and during the next month he increased the amount of activity daily.His height then was 168 cm.He wore a supporting leather jacket and on discharge from the ward, April 29, 1927, he could walk easily with the aid of a cane.
Primary care as part of US health services reform
Authors: B. Starfield
Journal: JAMA (1993)

RECENT history reflects a myriad of problems with the US health service system. In the 1960s, physician manpower shortages received the most attention from policymakers. When efforts to increase the number of physicians succeeded, maldistribution was recognized as a problem. In the 1970s, rapid increases in costs attracted attention and led to the development of several regulatory mechanisms, including the diagnosis related groups, to reduce expenditures associated with hospitalization. In the 1980s, observations of variations in physician practice patterns without concomitant variations in outcomes of care led to a realization that much of medical care lacked benefit, and the movement toward quality control and total quality improvement assumed prominence. In the 1990s, compromised access resulting from the absence of universal health insurance and excessive costs consequent to unnecessary care share the stage in the policy drama. See also p 3156. The poor development of primary care within the US health
Lenticular Opacities in Glaucoma Patients Receiving Echothiophate Iodide Therapy
Authors: Andrew de Roetth
Journal: JAMA (1966)

Echothiophatee) iodide has been used in ophthalmology for the past eight years.<sup>1</sup>During the last few years it has become one of the drugs most frequently employed in the treat ment of glaucoma. It is an irreversible inhibitor of cholinesterase and an excellent drug for control of chronic simple glaucoma, postiridectomy angle-closure glaucoma, and various secondary glaucomas.<sup>2,3</sup>However, unfavorable local and systemic side effects have been reported.<sup>4-7</sup>The most important local side effects are spasm of the ciliary muscle, producing severe pain in the eye, and edema of the anterior uveal tract which may result in angle closure and an acute attack of glaucoma. The systemic side effects include gastrointestinal, respiratory, cardiac, and central-nervous-system symptoms, which in their severest form potentially may even be lethal. During the past year many of my colleagues have noticed the development of cataracts in their glaucoma patients treated with echothiophate iodide.
Incorrect Information in Table 3
Authors: Anny Xiang
Journal: JAMA (2017)

Silvia Schönenberger, MD; Lorenz Uhlmann, MSc; Werner Hacke, MD, PhD; Simon Schieber, MD; Sibu Mundiyanapurath, MD; Jan C. Purrucker, MD; Simon Nagel, MD; Christina Klose; Johannes Pfaff, MD; Martin Bendszus, MD; Peter A. Ringleb, MD; Meinhard Kieser, PhD; Markus A. Möhlenbruch, MD; Julian Bösel, MD, FNCS
The AMA and the Physicians Committee for Responsible Medicine-Reply
Authors: Jerod M. Loeb
Journal: JAMA (1992)

<h3>In Reply.</h3> —The term "officially censured" refers to a resolution adopted by the AMA House of Delegates in June 1990 and noted in Dr Barnard's letter. Contrary to Barnard's statement, this resolution was debated fully in a Reference Committee hearing at which Barnard was present and at which he was given several opportunities to present his views in full. The Reference Committee heard overwhelming support for passage of this resolution and consequently recommended that it be included on the consent calendar for approval by the AMA House of Delegates. This procedure is traditionally reserved for those resolutions that the Reference Committee believes have strong and obvious support. The House of Delegates had ample opportunity to remove this item of business from the consent calendar for specific discussion on the floor of the House of Delegates but chose instead to move for passage. The resolution was passed without dissenting vote and
The art of pimping
Authors: F. L. Brancati
Journal: JAMA (1989)

IT'S HARD work becoming a revered attending physician in a university hospital. The task daunts the newly appointed junior attending as he strides down the corridor of his first ward with his first team. Oh, he's made some changes in anticipation of his new position. He's wearing a long coat now, an all-cotton coat with razor-sharp creases and knit buttons. The stained, shrunken polyester white pants and tennis shoes have given way to gray, light wool slacks with a cuff and polished loafers. Framed certificates bear testimony to his intelligence and determination. He should be ready to take the helm of his ward team, but he's not. Something's missing, something important, something closer to art than to science. When physicians talk about the "art of medicine" they usually mean healing, or coping with uncertainty, or calculating their federal income taxes. But there's one art this new attending needs to learn
Anatomy
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages
Authors: K. Kohri, J. Tamaoki, M Kondo, K Aoshiba, E Tagaya, A Nagai
Journal: European Respiratory Journal (2000)

There is evidence that macrolide antibiotics are effective in the treatment of chronic airway inflammatory diseases, probably through actions other than their antibacterial properties. In order to determine whether macrolides affect the nitric oxide-generating system in the respiratory tract, rat pulmonary alveolar macrophages (PAMs) were studied in vitro. The release of NO was assessed by direct measurement with a specific amperometric sensor for this molecule, and the expression of type II NO synthase (NOS) messenger ribonucleic acid (mRNA) was determined by Northern blotting. Incubation of PAMs with lipopolysaccharide from Escherichia coli and recombinant human interferon-gamma caused release of NO, which was accompanied by induction of type II NOS mRNA. The release of NO was reduced by coincubation of cells with the macrolides erythromycin, clarithromycin and josamycin in a concentration-dependent manner, the maximal inhibition being 73+/-10, 81+/-6 and 84+/-9%, respectively, but was not altered by amoxycillin or cefaclor. These macrolides likewise inhibited the induction of type II NOS mRNA, whereas no inhibitory effects were observed with amoxycillin or cefaclor. These results suggest that macrolide antibiotics specifically inhibit type II NO synthase gene expression and consequently reduce NO production by rat pulmonary alveolar macrophages, which might result in attenuation of airway inflammation.
Content analysis of postings in a stomach cancer survivor and caregiver support group on Facebook.
Authors: James Randolph Hillard
Journal: Journal of Clinical Oncology (2015)

e20566 Background: Patients diagnosed with cancer are increasingly turning to patient created social media groups to connect with others suffering from similar conditions. These groups allow sharing of information and support between their members, without involving medical or mental health professionals. This study examines the content of communications within one of these groups in order to identify the needs these groups are addressing, and in order to explore implications for mental health. Methods: This study focuses on a single Facebook group for stomach cancer patients and caregivers which has grown from 239 members a year ago to 1,850 members now and which has been operating for about four years. Two thirds of members are cancer patients, and the rest are caregivers. About 75% of members are from the US. The age range is 40-79, with a mean of 54. Members are 55% women, and 80% are middle class. Most members have been in the group for six to twelve months. The site averages about five original posts and about 50 responses a day. 100 consecutive posts were assigned to one of 12 pre-selected content categories. Results: Primary purpose of each of 100 consecutive posts (1) Sharing updates on their condition: 14 (2) Questions about treatment side effects: 13 (3) General requests for information: 13 (4) Requests for support or prayers: 11 (5) Sharing good news: 11 (6) Welcoming new members: 11 (7) Giving general support: 9 (8) Announcing a death: 5 (9) Sharing information about new treatments: 5 (10) Sharing humor: 4 (11) Sharing bad news: 2 (12) Asking
Deficiency of plasma platelet‐activating factor acetylhydrolase: Roles of blood cells
Authors: Hidemi Yoshida, Kei Satoh, Masayuki Koyama, Makoto Hiramoto, Shigeru Takamatsu
Journal: American Journal of Hematology (1996)

Platelet-activating factor (PAF), a potent mediator of inflammation and circulatory shock, is inactivated by the enzyme PAF acetylhydrolase. Plasma PAF acetylhydrolase deficiency occurs even in healthy subjects. We hypothesized that erythrocyte PAF acetylhydrolase could play a supplementary role in this plasma acetylhydrolase deficiency. We examined 1,030 subjects who participated in mass checkups, and assayed plasma and erythrocyte PAF acetylhydrolase. We also investigated the degradation of exogenous PAF by erythrocytes or other blood cells obtained from subjects who exhibited the plasma enzyme deficiency. The incidence of the plasma enzyme deficiency in this general Japanese population was 4.7% (48/1,030). None of the subjects with the deficiency had a history of allergy, circulatory shock, or chronic inflammatory diseases. The mean values for erythrocyte cytosolic PAF acetylhydrolase activity in the normal and deficient subjects were 0.51 ± 0.15 (SD) and 0.71 ± 0.28 nkat (nmol/s)/g protein, respectively, and the difference was significant (P < 0.001, Mann-Whitney U-test). The half-life of 10 nmol/l [3H]PAF in plasma from normal subjects was about 5 min, and the half-life in whole blood or erythrocyte suspension in autologous plasma was almost the same as that in plasma. In plasma from deficient subjects, unchanged PAF virtually remained and the degradation in whole blood or erythrocyte suspension was a little faster than in plasma. We conclude that erythrocytes contribute only little to PAF metabolism in normal blood but they account for almost all of the slow PAF degradation in blood from subjects deficient in plasma PAF acetylhydrolase. © 1996 Wiley-Liss, Inc.
Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort.
Authors: N. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, C. Yoshizawa, S. Shak, N. Siegelmann-Danieli
Journal: Journal of Clinical Oncology (2011)

632 Background: The Recurrence Score (RS) assay provides prognostic and predictive information for estrogen receptor positive (ER+) breast cancer. In a large cohort of ER+, HER2-, lymph node negative (LN-) patients (pts), the distribution of RS and RS groups, within categories of age, tumor size, grade, and joint categories (e.g., size versus grade) were examined. Methods: 2,097 pts from Clalit Health Services and 484 from Maccabi Health Services in Tel Aviv, Israel, had RS assay ordered between 1/2008 and 6/2010. 1864 were LN-, ER+, HER2- (LN- grade 3 tumors of MHS pts required to be < 2 cm). Pt age, tumor size and grade were obtained for 100%, 99% and 82% of cases. Distributions of RS were compared among categories of the clinicopathologic factors and Spearman correlation coefficients (and 95% confidence intervals) were calculated to assess the association between them. Results: 99.3% were female. Age distributions were: 23-40yo, 3.2%; 40-49yo , 16.5%; 50 - 59yo, 30.4%; 60-69yo, 32.8%; 70-85yo, 17.1%. Tumor sizes were: <1 cm, 12.5%; 1-2cm, 65.8%; >2-3cm, 17.3%; >3cm, 4.5%. By grade: 1, 18.1%; 2, 63%; 3, 18.9%. 79.7% were ductal and 12.5% lobular. 81.9% were IHC PR+. Spearman cc’s (and 95% CI) for continuous RS with standard metrics: age, -0.09 (-0.13,-0.04); tumor size (cm), 0.07 (0.02,0.12); tumor grade, 0.33 (0.28,0.37). Pts <50 yo, 14.2% had high RS; ≥50 yo 10.3% had high RS. In tumors ≤2 cm, 16% had high RS; > 2 cm 30.7% had high RS. 1.4% of grade 1 tumors had high RS and 30.7% had intermediate RS while 22.8 % of grade 3 tumors had low RS. 7.5% of PR+ tumors had high RS and 20.1% of PR- tumors had low RS. Joint categories will be presented. Conclusions: There is a range of RS biology across pt age, tumor size, grade. The RS can’t be predicted by clinicopathologic variables. Characteristic Value Low (RS<18) Int (RS 18-30) High (RS≥31) Age (years) <50 177 (48.2%) 138 (37.6%) 52 (14.2%) ≥50 763 (51.0%) 580 (38.7%) 154 (10.3%) Tumor size (cm) ≤2 247 (20.3%) 775 (63.7%) 194 (16.0%) >2 29 (9.5%) 183 (59.8%) 94 (30.7%) Tumor grade 1 188 (67.9%) 85 (30.7%) 4 (1.4%) 2 507 (52.6%) 366 (38.0%) 91 (9.4%) 3 66 (22.8%) 132 (45.7%) 91 (31.5%) PR by IHC Neg 67 (20.1%) 176 (52.9%) 90 (27.0%) Pos 860 (57.1%) 533 (35.4%) 113 (7.5%)